Linagliptin Add-on to Insulin Background Therapy

NCT02897349 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: placebo
DRUG: linagliptin
DRUG: background therapy

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]